The Unusual Suspects for the Week Ahead (BKS, BRCD, CSKI, CIEN, FNFG, NAL, GENZ, SNY, LULU, ID, NFLX, NE, PBR, RTN, SKS, TTWO, THQI, CALL) 247wallst.com - Sep 04, 2010   about  PBR, LULU, RTN and 15 moreNE, FNFG, THQI, NAL, TTWO, SKS, ID, VG, NFLX, CIEN, BRCD, SNY, CALL, GENZ, BKS The cast of characters in this week’s Unusual Suspects is not any ordinary group of companies.  There are many key stocks to watch for investors that have carryover issues from last week or which have upcoming events for the week.  There is a lot happening considering that earnings are quiet and con... add a comment   |

History Predicts Genzyme Will Sell For $80 Per Share minyanville.com - Sep 03, 2010   about  SNY, GENZ While M&A actually stands for mergers and acquisitions it should really be something more like mystery and artful maneuvering -- because those are two of the key ingredients that seem to surround most M&A. Investing in stocks that are rumored to be in negotiations or that have even confirmed... add a comment   |

Cooper Profit Grows, Lifts View zacks.com - Sep 03, 2010   about  COO Cooper Companies Inc. (COO) reported better-than-expected third-quarter fiscal 2010 (ended July 31, 2010) results with adjusted earnings per share of 91 cents outshining the Zacks Consensus Estimate of 71 cents and the year-ago earnings of 54 cents. add a comment   |

Rexahn Pharmaceuticals, Inc. (RNN) Announces Publication on the Anti-Tumor Activity of Novel Anticancer Compound RX-8243 straightstocks.com - Sep 03, 2010   about  RNN Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company dedicated to developing and commercializing first in class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs, recently announced that a research article on the anti-tumor a... add a comment   |

Genzyme (NASDAQ:GENZ): See 90% probablity GENZ gets $80/share - Leerink notablecalls.blogspot.com - Sep 03, 2010   about  GENZ Leerink Swann is now out commenting on Genzyme (NASDAQ:GENZ) upping their rating to Outperform (previously MP followed by NR).The firm is hosting a conference call at 11AM EST to discuss their analysis of historical unsolicited bids that has driven them to reinstitute an OP rating for GENZ.Leerink n... add a comment   |

Genzyme (NASDAQ:GENZ): See 90% probablity GENZ gets $80/share – Leerink straightstocks.com - Sep 03, 2010   about  GENZ Leerink Swann is now out commenting on Genzyme (NASDAQ:GENZ) upping their rating to Outperform (previously MP followed by NR).The firm is hosting a conference call at 11AM EST to discuss their analysis of historical unsolicited bids that has driven the... add a comment   |

Medtronic (MDT) Dividend Stock Analysis dividendgrowthinvestor.com - Sep 03, 2010   about  BDX, JNJ, BCR and 1 moreMDT Medtronic, Inc. (MDT) develops, manufactures, and sells device-based medical therapies worldwide. This dividend champion has raised distributions for 33 years in a row.Over the past decade this dividend stock has produced a negative total return of 2.20% per year. The company was grossly overvalued... add a comment   |

Martek Tops Zacks Consensus zacks.com - Sep 02, 2010   about  MATK Martek Biosciences CorporationÂ?s (MATK) third-quarter fiscal 2010 earnings (excluding special items) of 38 cents per share surpassed the Zacks Consensus Estimate by 2 cents and the year-ago earnings by 11 cents. add a comment   |

Alexion Remains Neutral zacks.com - Sep 02, 2010   about  ALXN We are maintaining our Neutral recommendation on Alexion Pharmaceuticals (ALXN) with a target price of $61. add a comment   |

Distribution Agreement for KCI zacks.com - Sep 02, 2010   about  KCI Medical technology company Kinetic ConceptsÂ? (KCI) business unit, LifeCell Corporation, entered into an agreement with Novadaq Technologies to distribute the latterÂ?s SPY imaging system in North American surgical markets. add a comment   |

Cooper Co. Jumps on FYQ3 Beat, Year EPS Forecast blogs.barrons.com - Sep 02, 2010   about  COO Shares of contact lense maker The Cooper Companies (COO) are up $1.86, or 4.5%, at $43 after the company handily beat fiscal Q3 EPS estimates and forecast the current quarter and the year’s profit above expectations. Q3 revenue per share rose almost 19% to $295.6 million, in line with estimates, but... add a comment   |

Forest Faces a Positive-Leaning Panel minyanville.com - Sep 02, 2010   about  FRX While Forest Laboratories (FRX) faces an uncertain future due to the upcoming patent losses of some of its biggest revenue-generating products over the next couple of years the biotech could be on the verge of getting approval for one product that will be able to stanch some of the bleeding. On Thur... add a comment   |

Orexigen Therapeutics (OREX) and Takeda Pharmaceutical to Commercialize Contrave in North America straightstocks.com - Sep 02, 2010   about  OREX Orexigen Therapeutics is a biopharmaceutical company focused on the treatment of obesity. The company filed a New Drug Application (NDA) with the US Food and Drug Administration (FDA) for its lead investigational product for the treatment of obesity – Contrave – on March 10,2010. The company anno... add a comment   |

Bad News for Israel ETF minyanville.com - Sep 02, 2010   about  EIS, MSC, TEVA and 1 moreCEL Editor's Note: This content was originally published on Benzinga.com. Ever wonder why the iShares MSCI Israel Capped Index Fund (EIS) has lagged this year while other emerging markets ETFs have surged? The answer is simple: Israel is no longer an emerging market and the change in status to developed... add a comment   |

Distribution Agreement for KCI – Analyst Blog straightstocks.com - Sep 02, 2010   about  KCI Medical technology company Kinetic Concepts’ (KCI) business unit, LifeCell Corporation, entered into an agreement with Novadaq Technologies to distribute the latter’s SPY imaging system in North American surgical markets. add a comment   |

Alexion Remains Neutral – Analyst Blog straightstocks.com - Sep 02, 2010   about  ALXN We are maintaining our Neutral recommendation on Alexion Pharmaceuticals (ALXN) with a target price of $61. add a comment   |

Martek Tops Zacks Consensus – Analyst Blog straightstocks.com - Sep 02, 2010   about  MATK Martek Biosciences Corporation’s (MATK) third-quarter fiscal 2010 earnings (excluding special items) of 38 cents per share surpassed the Zacks Consensus Estimate by 2 cents and the year-ago earnings by 11 cents. add a comment   |

Analyst Calls: BSX, FORM, HPQ, JACK, MCO, NFLX, PPL, RTP, VALE ... pheedcontent.com - Sep 02, 2010   about  RTP, NFLX, BSX and 1 moreHPQ Filed under: Analyst Reports, Analyst Upgrades and Downgrades, Hewlett-Packard (HPQ), Netflix, Inc. (NFLX), Boston Scientific (BSX), Analyst Initiations, Rio Tinto plc ADS (RTP)Analyst Upgrades JMP Securities upgraded Hewlett-Packard (HPQ) to outperform from market perform based on valuation an... add a comment   |

Orexigen Fattens Its Coffers With Takeda Cash minyanville.com - Sep 02, 2010   about  OREX Orexigen Therapeutics (OREX) finally becomes a major competitor in the race to get an obesity drug on the market. The oft-in-the-shadows biotech has garnered a pair-up with Japan's Takeda Pharmaceuticals for the commercialization of its obesity drug Contrave in the United States Canada and Mexico in... add a comment   |

Chart Watch: Minyanville Buzz Charts minyanville.com - Sep 02, 2010   about  BMY, BAC, TBT and 2 moreBSX, QCOM Below are some of the most-discussed charts on Minyanville's Buzz & Banter presented without bias claim or injury. For in-depth commentary analysis and trading ideas in these stocks and much more take a free two week trial to Buzz & Banter. Bristol Myers Squibb (BMY)CLICK TO ENLARGE Qualcomm... add a comment   |

« Previous   Next »